Evercore ISI raised the firm’s price target on Cencora (COR) to $400 from $340 and keeps an Outperform rating on the shares. The company is setting the stage for its next growth phase with a solid Q4 performance and strategic resegmentation, the analyst tells investors in a research note. The firm added that the new structure, effective 1Q26, refocuses on core human health distribution while isolating non-core assets, which could be monetized or repositioned.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR: